Award notice Supplies

Infliximab

Notice published in Dutch. The AI analysis summarises it for you in your language.

Official notice and documents

Public buyer: AZ Delta vzw
Roeselare
Place of performance: 8800 Roeselare, West Flanders
Amount awarded: €1,450,176 excl. VAT
Planned end of contract: 31 July 2029
likely re-tender around January 2029
Bids received: 2
Form: Framework agreement
Multi-year contract: the buyer places orders as needs arise.
Procedure: Open procedure
Any company may submit a bid.
Publication: 4 August 2025
Notice language: Dutch

AI analysis: go for it or not?

Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.

Create my free account

Unlimited analyses during the 14-day Pro trial, no card needed.

Description

Deze opdracht omvat het sluiten van een raamovereenkomst voor de levering van infliximab voor een periode van één jaar en driemaal stilzwijgend verlengbaar voor telkens één jaar.

Awarded to

Sandoz NV BCE/KBO 0457.517.227

CPV codes

European codes that classify what the contract is about. They are how we find the tenders for your trade.

33600000

Winning prices for comparable contracts

A quarter below: €269,390
Median: €449,863
A quarter above: €962,736

Amounts awarded (excl. VAT) over the last 3 years for 58 contracts in the same CPV group (3360…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.

Similar contracts already awarded

Contract	Winner	Amount
Nintedanib en pirfenidon AZ Delta vzw · 6 October 2026	Accord Healthcare BV Aurobindo NV	€1,080,061
Aflibercept AZ Delta vzw · 8 September 2026	Celltrion Healthcare Netherlands BV	€4,424,940
Denosumab SC AZ Delta vzw · 16 July 2026	Amgen NV	€389,080
Tocilizumab IV AZ Delta vzw · 18 June 2026	Celltrion Healthcare Netherlands BV	€385,370
Parenterale cytostatica AZ Delta vzw · 7 April 2026	Celltrion Healthcare Netherlands BV Sandoz NV Accord Healthcare BV Arega Pharma NV Aurobindo NV Fresenius Kabi NV Pharmanovia Benelux BV Grindeks-Kalceks Belgium BV Viatris BV EG NV Pharma Mar BV Roche NV	€3,950,688

Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 508528-2025.